NASDAQ: CAI
Caris Life Sciences, Inc.
Healthcare · Biotechnology
After hours: $22.43(-1.36%) · as of 4:56 PM ET
Market Cap
$6.43B
52w High
$42.50
52w Low
$14.19
P/E
61.19
Volume
0.00
Outstanding Shares
282.68M
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 20.46% over the last year. Revenue grew 85.37% over the trailing twelve months. Operating margin moved from -25.82% to 15.49%. Free cash flow grew 204.2% over the trailing twelve months.
What the market seems to be pricing
Visible fundamentals weakened far less than the stock price. The market appears to be discounting durability, risk, or trust rather than just the latest reported numbers.
What would invalidate this read
This read changes if operating margin (currently 15.49%) continues to decline, or if revenue growth turns negative. The bull case requires the business to hold its current trajectory.
Company profile
Caris Life Sciences, Inc. operates as a leading "TechBio" firm, harnessing artificial intelligence to deliver comprehensive molecular profiling services to clients both in the United States and internationally.
Valuation
Stock splits
No stock splits recorded for this ticker.
Profitability & growth
Analyst consensus
6
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.
Next report
Nov 4, 2026
Q4 FY26 · EPS est $0.02 · Revenue est $258.52M
View